This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at [email protected] or call + 1 (702) 988 2320.
Precision medicine's goal is to use vast multidimensional biological datasets to build and enhance diagnosis, therapeutic intervention, and prognosis pathways that reflect individual diversity in genes, function, and environment. Artificial intelligence (AI) algorithms can currently forecast risk in some malignancies and cardiovascular diseases from available multidimensional clinical and biological data with fair accuracy due to high computer capabilities. Diabetes AI assistants have been proved to be effective in managing patient problems. As artificial intelligence (AI) becomes more prevalent in precision medicine, it can assist organizations in a variety of ways. In terms of data issues, AI employs deep learning techniques to solve the difficulties that massive data sets and unstructured data provide.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain